In conclusion, results from four large phase 3 trials comparing the investigational drug vadadustat with an ESA, darbepoetin, demonstrated that vadadustat can increase endogenous EPO production, improve erythroblast iron availability, and increase circulating reticulocytes in patients with CKD and anemia. Here, EPO is linked to anemia (phenotype).